middle.news
LTR Pharma’s OROFLOW® Gains Ethics Nod to Target $8 Billion Oesophageal Motility Market
8:22am on Wednesday 24th of June, 2026 AEST
•
Healthcare
Read Story
LTR Pharma’s OROFLOW® Gains Ethics Nod to Target $8 Billion Oesophageal Motility Market
8:22am on Wednesday 24th of June, 2026 AEST
Key Points
Ethics approval for OROFLOW® clinical study in oesophageal motility disorders
Investigator-initiated trial led by Dr Peter Wu at St George Hospital
Potential non-invasive alternative to surgery and invasive treatments
OMD market forecast to hit US$8.1 billion by 2034
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Ltr Pharma (ASX:LTP)
OPEN ARTICLE